DK3273995T3 - Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion - Google Patents
Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion Download PDFInfo
- Publication number
- DK3273995T3 DK3273995T3 DK16711320.8T DK16711320T DK3273995T3 DK 3273995 T3 DK3273995 T3 DK 3273995T3 DK 16711320 T DK16711320 T DK 16711320T DK 3273995 T3 DK3273995 T3 DK 3273995T3
- Authority
- DK
- Denmark
- Prior art keywords
- cftr
- alginatoligomers
- lumacaftor
- treatment
- conditions associated
- Prior art date
Links
- 230000004064 dysfunction Effects 0.000 title 1
- UFSKUSARDNFIRC-UHFFFAOYSA-N lumacaftor Chemical compound N1=C(C=2C=C(C=CC=2)C(O)=O)C(C)=CC=C1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 UFSKUSARDNFIRC-UHFFFAOYSA-N 0.000 title 1
- 229960000998 lumacaftor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1504878.8A GB201504878D0 (en) | 2015-03-23 | 2015-03-23 | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
PCT/EP2016/056458 WO2016151051A1 (en) | 2015-03-23 | 2016-03-23 | Use of alginate oligomers and cftr modulators in the treatment of conditions associated with cftr dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3273995T3 true DK3273995T3 (da) | 2021-10-18 |
Family
ID=53052244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16711320.8T DK3273995T3 (da) | 2015-03-23 | 2016-03-23 | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion |
Country Status (7)
Country | Link |
---|---|
US (1) | US10751363B2 (da) |
EP (1) | EP3273995B1 (da) |
AU (1) | AU2016236172B2 (da) |
CA (1) | CA2980104A1 (da) |
DK (1) | DK3273995T3 (da) |
GB (1) | GB201504878D0 (da) |
WO (1) | WO2016151051A1 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
FR3057011B1 (fr) * | 2016-10-03 | 2018-11-02 | S.P.C.M. Sa | Appareil de regulation de pression d'injection pour la recuperation assistee du petrole par polymere |
CN106596488A (zh) * | 2016-12-14 | 2017-04-26 | 蔡璇 | 一种食品中磺胺残留量快速检测方法 |
EP3565848A4 (en) | 2017-01-03 | 2020-09-02 | The University of North Carolina at Chapel Hill | NITROGEN OXIDE RELEASING ALGINATES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDINGS AND ASSOCIATED PROCESSES |
US11723914B2 (en) | 2017-03-28 | 2023-08-15 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
EP3762039A4 (en) | 2018-03-06 | 2021-12-22 | The University of North Carolina at Chapel Hill | NITRIC OXIDE RELEASING CYCLODEXTRINS AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES |
KR20200136430A (ko) * | 2018-03-19 | 2020-12-07 | 알지파마 에이에스 | 점액 층을 가로지르는 마이크로/나노입자의 전위를 향상시키기 위한 알지네이트 올리고머의 용도 |
WO2020139857A1 (en) | 2018-12-28 | 2020-07-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
EP4081310A4 (en) | 2019-12-26 | 2024-03-27 | Nat Jewish Health | METHODS OF TREATING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) DYSFUNCTION |
US20230181610A1 (en) * | 2021-10-18 | 2023-06-15 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and Compositions for Treatment of Cystic Fibrosis Class I Mutations |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8805695D0 (en) | 1988-03-10 | 1988-04-07 | Nycomed As | Enteric coated spheroidal granules |
WO1991011205A1 (en) | 1990-01-23 | 1991-08-08 | Trancel Corporation | Mannuronic acid containing alginate wound healing composition and method |
US5169840A (en) | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
GB9221163D0 (en) | 1992-10-08 | 1992-11-25 | Nobipol And Protan Biopolymer | Dna compounds |
NO305033B1 (no) | 1997-05-09 | 1999-03-22 | Algipharma As | Fremgangsmate for fremstilling av uronsyreblokker fra alginat |
AR030557A1 (es) | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
NO326145B1 (no) | 2001-11-30 | 2008-10-06 | Fmc Biopolymer As | Fremgangsmate for a stimulere vektokning hos pattedyr, fugler og krypdyr. |
NO20023581D0 (no) | 2002-07-26 | 2002-07-26 | Fmc Biopolymer As | Nye mutantstammer av Pseudomonas fluorescens og varianter derav, metoder for produksjon og bruk derav til produksjon avalginat |
EP2522659A3 (en) | 2004-06-24 | 2013-11-27 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
GB2430881B (en) | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
PL2774925T3 (pl) | 2005-11-08 | 2017-07-31 | Vertex Pharmaceuticals Incorporated | Heterocykliczne modulatory transporterów z kasetą wiążącą ATP |
CA2652072A1 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
GB0707096D0 (en) * | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
CN101918366A (zh) | 2007-09-14 | 2010-12-15 | 弗特克斯药品有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式 |
WO2009064959A1 (en) | 2007-11-16 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Isoquinoline modulators of atp-binding cassette transporters |
CN107050047B (zh) | 2007-11-27 | 2021-06-11 | 阿尔吉法玛公司 | 无菌水类或无菌油类清创组合物和包含组合制剂的产品 |
NZ585794A (en) | 2007-12-07 | 2012-05-25 | Vertex Pharma | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
EP2225230B1 (en) | 2007-12-07 | 2016-11-16 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
EA201070699A1 (ru) | 2007-12-07 | 2011-02-28 | Вертекс Фармасьютикалз Инкорпорейтед | Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
EP3345625B1 (en) | 2008-08-13 | 2020-12-09 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
EP2349223A2 (en) | 2008-09-29 | 2011-08-03 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
JP5645833B2 (ja) | 2008-10-23 | 2014-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜コンダクタンス制御因子の修飾因子 |
PL2365972T3 (pl) | 2008-11-06 | 2015-05-29 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą ATP |
UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
AU2010255542B2 (en) | 2009-06-03 | 2015-12-24 | Algipharma As | Treatment of Acinetobacter with alginate oligomers and antibiotics |
CN102665715A (zh) | 2009-10-22 | 2012-09-12 | 沃泰克斯药物股份有限公司 | 治疗囊性纤维化和其他慢性疾病的组合物 |
DK2555754T3 (da) | 2010-04-07 | 2016-04-18 | Vertex Pharma | Faste former af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre |
HUE056525T2 (hu) | 2010-04-07 | 2022-02-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása |
EP2560651A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
EP2560954B1 (en) | 2010-04-22 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
EP2560650A1 (en) * | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
NZ603042A (en) | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
NZ603386A (en) | 2010-05-20 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions and administrations thereof |
EP2608775A2 (en) | 2010-08-27 | 2013-07-03 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
KR20150000110A (ko) | 2013-06-24 | 2015-01-02 | 재단법인 전남생물산업진흥원 | 알긴산을 포함하는 천식 예방 또는 치료용 조성물 |
AU2015222051A1 (en) | 2014-02-28 | 2016-10-13 | Algipharma As | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective CFTR ion channel function |
-
2015
- 2015-03-23 GB GBGB1504878.8A patent/GB201504878D0/en not_active Ceased
-
2016
- 2016-03-23 EP EP16711320.8A patent/EP3273995B1/en active Active
- 2016-03-23 DK DK16711320.8T patent/DK3273995T3/da active
- 2016-03-23 AU AU2016236172A patent/AU2016236172B2/en active Active
- 2016-03-23 WO PCT/EP2016/056458 patent/WO2016151051A1/en active Application Filing
- 2016-03-23 CA CA2980104A patent/CA2980104A1/en active Pending
- 2016-03-23 US US15/560,984 patent/US10751363B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3273995B1 (en) | 2021-07-14 |
WO2016151051A1 (en) | 2016-09-29 |
EP3273995A1 (en) | 2018-01-31 |
US10751363B2 (en) | 2020-08-25 |
AU2016236172A1 (en) | 2017-10-12 |
US20180055873A1 (en) | 2018-03-01 |
GB201504878D0 (en) | 2015-05-06 |
AU2016236172B2 (en) | 2021-07-01 |
CA2980104A1 (en) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
DK3334422T3 (da) | Anvendelse af cannabidiolsyre i behandling af epilepsi | |
DK3099717T3 (da) | Antistofmolekyler med tim-3 og anvendelser deraf | |
DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
DK3325509T3 (da) | Anti-tfr antistoffer og deres anvendelse i behandling af proliferative og inflammatoriske lidelser | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
GB2539350B (en) | Amyloid targeting agents and methods of using the same | |
DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
DK3076972T3 (da) | Cancerbehandling med kombination af plinabulin og taxan | |
DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
DK3576738T3 (da) | Gaboxadolmonohydrat i behandling af tinnitus | |
DK3233066T3 (da) | Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3116897T3 (da) | Polymyxinderivater og deres anvendelse i kombinationsterapi sammen med forskellige antibiotika | |
DK3442513T3 (da) | Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser | |
DK3619362T3 (da) | Forbedringer af og i forbindelse med barrierer | |
DK3362449T3 (da) | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose | |
DK3722291T3 (da) | Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme | |
DK3297651T3 (da) | Synergistisk kombination af neuronale levedygtighedsfaktorer og anvendelser deraf | |
DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier |